Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 12, 2016, Pages 1706-1719.e5

  Tran Duy, An ^a   Spaetgens, Bart ^a   Hoes, Arno W ^b   de Wit, Niek J ^b   Stehouwer, Coen D A ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Acid Suppressive Drug; Neoplasm; Side Effect; Stomach Carcinoma

Indexed keywords

PROTON PUMP INHIBITOR;

CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONFOUNDING VARIABLE; DATA ANALYSIS; DISEASE ASSOCIATION; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; ODDS RATIO; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STOMACH CANCER; STOMACH FUNDUS GLAND; STOMACH FUNDUS GLAND POLYP; STOMACH POLYP; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT DURATION; CHEMICALLY INDUCED; POLYPS; STOMACH NEOPLASMS;

HUMANS; OBSERVATIONAL STUDIES AS TOPIC; POLYPS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STOMACH NEOPLASMS;

EID: 85015649552     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.05.018     Document Type: Review

References (69)

1. 1 Shin, J.M., Sachs, G., Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 10 (2008), 528–534.
2. 2 Stolte, M., Sticht, T., Eidt, S., et al. Frequency, location, and age and sex distribution of various types of gastric polyp. Endoscopy 26 (1994), 659–665.
3. 3 Odze, R.D., Marcial, M.A., Antonioli, D., Gastric fundic gland polyps: a morphological study including mucin histochemistry, stereometry, and MIB-1 immunohistochemistry. Hum Pathol 27 (1996), 896–903.
4. 4 Sipponen, P., Laxen, F., Seppala, K., Cystic ‘hamartomatous’ gastric polyps: a disorder of oxyntic glands. Histopathology 7 (1983), 729–737.
5. 5 Lee, R.G., Burt, R.W., The histopathology of fundic gland polyps of the stomach. Am J Clin Pathol 86 (1986), 498–503.
6. 6 Kinoshita, Y., Tojo, M., Yano, T., et al. Incidence of fundic gland polyps in patients without familial adenomatous polyposis. Gastrointest Endosc 39 (1993), 161–163.
7. 7 Iida, M., Yao, T., Itoh, H., et al. Natural history of fundic gland polyposis in patients with familial adenomatosis coli/Gardner's syndrome. Gastroenterology 89 (1985), 1021–1025.
8. 8 Graham, J., Gastric polyposis: onset during long-term therapy with omeprazole. Med J Aust 157 (1992), 287–288.
9. 9 Stolte, M., Bethke, B., Seifert, E., et al. Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment. Z Gastroenterol 33 (1995), 146–149.
10. 10 Van Vlierberghe, H., De Vos, M., De Cock, G., et al. Fundic gland polyps: three other case reports suggesting a possible association with acid suppressing therapy. Acta Gastroenterol Belg 60 (1997), 240–242.
11. 11 Kazantsev, G.B., Schwesinger, W.H., Heim-Hall, J., Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with lansoprazole and Nissen fundoplication: a case report. Gastrointest Endosc 55 (2002), 600–602.
12. 12 Flick, A.L., Gastric fundal polyps with cellular atypia in a patient using esomeprazole (Nexium). Dig Dis Sci 50 (2005), 2100–2102.
13. 13 Kim, J.S., Chae, H.S., Kim, H.K., et al. Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with omeprazole. Korean J Gastroenterol 51 (2008), 305–308.
14. 14 Spiegel, A., Stein, P., Patel, M., et al. A report of gastric fundic gland polyps. Gastroenterol Hepatol 6 (2010), 45–48.
15. 15 Hegedus, I., Csizmadia, C., Lomb, Z., et al. Massive fundic gland polyposis caused by chronic proton pump inhibitor therapy. [Hungarian] Tartos protonpumpagatlo kezeles hatasara kialakulo massziv fundusmirigy-polyposis. Orv Hetil 153 (2012), 351–356.
16. 16 Abraham, S.C., Nobukawa, B., Giardiello, F.M., et al. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol 157 (2000), 747–754.
17. 17 Abraham, S.C., Nobukawa, B., Giardiello, F.M., et al. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol 158 (2001), 1005–1010.
18. 18 Carmack, S.W., Genta, R.M., Schuler, C.M., et al. The current spectrum of gastric polyps: A 1-year national study of over 120,000 patients. Am J Gastroenterol 104 (2009), 1524–1532.
19. 19 Wu, T.T., Kornacki, S., Rashid, A., et al. Dysplasia and dysregulation of proliferation in foveolar and surface epithelia of fundic gland polyps from patients with familial adenomatous polyposis. Am J Surg Pathol 22 (1998), 293–298.
20. 20 Jalving, M., Koornstra, J.J., Gotz, J.M., et al. High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol 15 (2003), 1229–1233.
21. 21 Havu, N., Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 35 (1986), 42–55.
22. 22 Ali, T., Roberts, D.N., Tierney, W.M., Long-term safety concerns with proton pump inhibitors. Am J Med 122 (2009), 896–903.
23. 23 Schenk, B.E., Kuipers, E.J., Klinkenberg-Knol, E.C., et al. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther 12 (1998), 605–612.
24. 24 Verdu, E.F., Armstrong, D., Fraser, R., et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 36 (1995), 539–543.
25. 25 Gillen, D., Wirz, A.A., Neithercut, W.D., et al. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 44 (1999), 468–475.
26. 26 Sanduleanu, S., Jonkers, D., De Bruine, A., et al. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: Differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther 15 (2001), 379–388.
27. 27 Sanduleanu, S., Jonkers, D., De Bruine, A., et al. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther 15 (2001), 1163–1175.
28. 28 Song, H., Ekheden, I.G., Zheng, Z., et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ, 351, 2015, h3867.
29. 29 Wroblewski, L.E., Peek, R.M., Wilson, K.T., Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk. Clin Microbiol Rev 23 (2010), 713–739.
30. 30 Higgins, J.P.T., Green, S., (eds.) Cochrane Handbook for Systematic Reviews of Interventions: Version 5.1.0, 2011, The Cochrane Collaboration Available: http://www.cochrane-handbook.org (accessed 25 December 2015).
31. 31 Wells GA, Shea B, O'Connell D, et al., editors. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2012. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed December 25, 2015.
32. 32 Higgins, J., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002), 1539–1558.
33. 33 Egger, M., Smith, G.D., Schneider, M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
34. 34 Viechtbauer, W., Conducting meta-analyses in R with the metafor package. J Stat Softw 36 (2010), 1–48.
35. 35 Moher, D., Liberati, A., Tetzlaff, J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151 (2009), 264–269.
36. 36 Stroup, D.F., Berlin, J.A., Morton, S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283 (2000), 2008–2012.
37. 37 Peura, D.A., Metz, D.C., Dabholkar, A.H., et al. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: Global clinical trial experience. Aliment Pharmacol Ther 30 (2009), 1010–1021.
38. 38 Choudhry, U., Boyce, H.W. Jr., Coppola, D., Proton pump inhibitor-associated gastric polyps: A retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 110 (1998), 615–621.
39. 39 Vieth, M., Stolte, M., Fundic gland polyps are not induced by proton pump inhibitor therapy. Am J Clin Pathol 116 (2001), 716–720.
40. 40 Jalving, M., Koornstra, J.J., Wesseling, J., et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 24 (2006), 1341–1348.
41. 41 Ally, M.R., Veerappan, G.R., Maydonovitch, C.L., et al. Chronic proton pump inhibitor therapy associated with increased development of fundic gland polyps. Dig Dis Sci 54 (2009), 2617–2622.
42. 42 Hsu, W.H., Wu, I.C., Kuo, C.H., et al. Influence of Proton Pump Inhibitor Use in Gastrointestinal Polyps. Kaohsiung J Med Sci 26 (2010), 76–83.
43. 43 Zelter, A., Fernandez, J.L., Bilder, C., et al. Fundic gland polyps and association with proton pump inhibitor intake: A prospective study in 1,780 endoscopies. Dig Dis Sci 56 (2011), 1743–1748.
44. 44 Cao, H.L., Qu, R., Zhang, Z.H., et al. Sporadic fundic gland polyps are not associated with proton pump inhibitors therapy but negatively correlate with Helicobacter pylori infection in China. Chin Med J (Engl) 127 (2014), 1239–1243.
45. 45 Poulsen, A.H., Christensen, S., McLaughlin, J.K., et al. Proton pump inhibitors and risk of gastric cancer: A population-based cohort study. Br J Cancer 100 (2009), 1503–1507.
46. 46 Garcia Rodriguez, L.A., Lagergren, J., Lindblad, M., Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: A nested case control study in the UK. Gut 55 (2006), 1538–1544.
47. 47 Crane, S.J., Locke, I.G.R., Harmsen, W.S., et al. Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol 102 (2007), 1596–1602.
48. 48 Tamim, H., Duranceau, A., Chen, L.Q., et al. Association between use of acid-suppressive drugs and risk of gastric cancer: A nested case-control study. Drug Saf 31 (2008), 675–684.
49. 49 Dickey, W., Kenny, B.D., McConnell, J.B., Prevalence of fundic gland polyps in a western European population. J Clin Gastroenterol 23 (1996), 73–75.
50. 50 Sakai, N., Tatsuta, M., Hirasawa, R., et al. Low prevalence of Helicobacter pylori infection in patients with hamartomatous fundic polyps. Dig Dis Sci 43 (1998), 766–772.
51. 51 Watanabe, N., Seno, H., Nakajima, T., et al. Regression of fundic gland polyps following acquisition of Helicobacter pylori. Gut 51 (2002), 742–745.
52. 52 Genta, R.M., Schuler, C.M., Robiou, C.I., et al. No Association Between Gastric Fundic Gland Polyps and Gastrointestinal Neoplasia in a Study of Over 100,000 Patients. Clin Gastroenterol Hepatol 7 (2009), 849–854.
53. 53 Graham, J.R., Omeprazole and gastric polyposis in humans. Gastroenterology, 104, 1993, 1584.
54. 54 Collins, S., Tydd, T., Gastric polyps and long-term omeprazole. J Gastroenterol Hepatol, 13, 1998, A149.
55. 55 Mogadam, M., Houk, R., Long-term use of omeprazole is associated with development of benign epithelial gastric polyps. Am J Gastroenterol, 91, 1996, A151.
56. 56 Reekmans, A., Naegels, S., Urbain, D., Fundic gland polyps and chronic PPI treatment: a prospective study. Gastroenterology, 120, 2001, A244.
57. 57 Archimandritis, A., Spiliadis, C., Tzivras, M., et al. Gastric epithelial polyps: a retrospective endoscopic study of 12974 symptomatic patients. Ital J Gastroenterol 28 (1996), 387–390.
58. 58 Marcial, M.A., Villafana, M., Hernandez-Denton, J., et al. Fundic gland polyps: prevalence and clinicopathologic features. Am J Gastroenterol 88 (1993), 1711–1713.
59. 59 Papa, A., Cammarota, G., Tursi, A., et al. Histologic types and surveillance of gastric polyps: a seven year clinico-pathological study. Hepatogastroenterology 45 (1998), 579–582.
60. 60 Weinstein, W., Ang, S., Ippoliti, A., et al. Fundic gland polyps in patients on long term omeprazole therapy: a light and electron microscopic study of the gastric mucosa. Gastroenterology, 106, 1994, A210.
61. 61 Hirt, M., Lee, S., Weinstein, W., Fundic gland polyps: a comparison of the omeprazole-associated and the sporadic types. Gastroenterology, 110, 1996, A135.
62. 62 Attard, T.M., Yardley, J.H., Cuffari, C., Gastric polyps in pediatrics: an 18-year hospital-based analysis. Am J Gastroenterol 97 (2002), 298–301.
63. 63 Ahn, J.S., Eom, C.S., Jeon, C.Y., et al. Acid suppressive drugs and gastric cancer: A meta-analysis of observational studies. World J Gastroenterol 19 (2013), 2560–2568.
64. 64 Weeks, D.L., Eskandari, S., Scott, D.R., et al. A H+-gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Science 287 (2000), 482–485.
65. 65 Kuipers, E.J., Uyterlinde, A.M., Pena, A.S., et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: Implications for long-term safety. Am J Gastroenterol 90 (1995), 1401–1406.
66. 66 Kuipers, E.J., Lundell, L., Klinkenberg-Knol, E.C., et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334 (1996), 1018–1022.
67. 67 Lundell, L., Havu, N., Miettinen, P., et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 23 (2006), 639–647.
68. 68 Uemura, N., Okamoto, S., Yamamoto, S., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345 (2001), 784–789.
69. 69 Fass, R., Chey, W.D., Zakko, S.F., et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther 29 (2009), 1261–1272.